MAO-B inhibitors for the treatment of Parkinson’s disease

John Bertoni; Diego R. Torres-Russotto

doi:10.1201/b12948

MAO-B inhibitors for the treatment of Parkinson’s disease

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Monoamine oxidases (MAO) are crucial enzymes that oxidatively deaminate monoamines (amines that have only one amino group, such as serotonin, epinephrine, norepinephrine, dopamine, tyramine, and tryptamine). There are two main forms of MAO. MAO-A predominates in the gut, spleen, and pancreas, and especially the placenta, and is inhibited by clorgyline [1]. MAO-B predominates in the human brain, skin, and skeletal muscle and is inhibited by deprenyl and pargyline [1]. Recent reviews of MAO inhibitors (MAOI) are available [2].

Original language	English (US)
Title of host publication	Parkinson's Disease, Second Edition
Publisher	CRC Press
Pages	825-838
Number of pages	14
ISBN (Electronic)	9781439807156
ISBN (Print)	9781439807149
DOIs	https://doi.org/10.1201/b12948
State	Published - Jan 1 2012

ASJC Scopus subject areas

General Neuroscience
General Medicine

Access to Document

10.1201/b12948

Cite this

@inbook{d84de847034747cbbabf3079fe50b4d6,

title = "MAO-B inhibitors for the treatment of Parkinson{\textquoteright}s disease",

abstract = "Monoamine oxidases (MAO) are crucial enzymes that oxidatively deaminate monoamines (amines that have only one amino group, such as serotonin, epinephrine, norepinephrine, dopamine, tyramine, and tryptamine). There are two main forms of MAO. MAO-A predominates in the gut, spleen, and pancreas, and especially the placenta, and is inhibited by clorgyline [1]. MAO-B predominates in the human brain, skin, and skeletal muscle and is inhibited by deprenyl and pargyline [1]. Recent reviews of MAO inhibitors (MAOI) are available [2].",

author = "John Bertoni and Torres-Russotto, {Diego R.}",

note = "Publisher Copyright: {\textcopyright} 2013 by Taylor & Francis Group, LLC.",

year = "2012",

month = jan,

day = "1",

doi = "10.1201/b12948",

language = "English (US)",

isbn = "9781439807149",

pages = "825--838",

booktitle = "Parkinson's Disease, Second Edition",

publisher = "CRC Press",

}

TY - CHAP

T1 - MAO-B inhibitors for the treatment of Parkinson’s disease

AU - Bertoni, John

AU - Torres-Russotto, Diego R.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Monoamine oxidases (MAO) are crucial enzymes that oxidatively deaminate monoamines (amines that have only one amino group, such as serotonin, epinephrine, norepinephrine, dopamine, tyramine, and tryptamine). There are two main forms of MAO. MAO-A predominates in the gut, spleen, and pancreas, and especially the placenta, and is inhibited by clorgyline [1]. MAO-B predominates in the human brain, skin, and skeletal muscle and is inhibited by deprenyl and pargyline [1]. Recent reviews of MAO inhibitors (MAOI) are available [2].

AB - Monoamine oxidases (MAO) are crucial enzymes that oxidatively deaminate monoamines (amines that have only one amino group, such as serotonin, epinephrine, norepinephrine, dopamine, tyramine, and tryptamine). There are two main forms of MAO. MAO-A predominates in the gut, spleen, and pancreas, and especially the placenta, and is inhibited by clorgyline [1]. MAO-B predominates in the human brain, skin, and skeletal muscle and is inhibited by deprenyl and pargyline [1]. Recent reviews of MAO inhibitors (MAOI) are available [2].

UR - http://www.scopus.com/inward/record.url?scp=85055806205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055806205&partnerID=8YFLogxK

U2 - 10.1201/b12948

DO - 10.1201/b12948

M3 - Chapter

AN - SCOPUS:85055806205

SN - 9781439807149

SP - 825

EP - 838

BT - Parkinson's Disease, Second Edition

PB - CRC Press

ER -

MAO-B inhibitors for the treatment of Parkinson’s disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this